Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

ClinicalTrials.gov ID: NCT00454909

Public ClinicalTrials.gov record NCT00454909. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.

Study identification

NCT ID
NCT00454909
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
873 participants

Conditions and interventions

Interventions

  • Meningococcal vaccine 134612 Biological
  • Menactra® Biological

Biological

Eligibility (public fields only)

Age range
10 Years to 25 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 22, 2007
Primary completion
Oct 30, 2007
Completion
Apr 10, 2008
Last update posted
Jun 7, 2018

2007 – 2008

United States locations

U.S. sites
10
U.S. states
2
U.S. cities
9
Facility City State ZIP Site status
GSK Investigational Site Daly City California 94015
GSK Investigational Site Fairfield California 94533
GSK Investigational Site Redwood City California 94063
GSK Investigational Site Sacramento California 95815
GSK Investigational Site Vallejo California 94589
GSK Investigational Site Walnut Creek California 94596
GSK Investigational Site Honolulu Hawaii 96814
GSK Investigational Site Honolulu Hawaii 96819
GSK Investigational Site Waianae Hawaii 96792
GSK Investigational Site Waipio Hawaii 96797

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00454909, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2018 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00454909 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →